Markets
Wall Street Caution Tape
(Adam Gray/Getty Images)

Analyst: “Technically, the market does not look healthy right now”

Here’s what he’s waiting to see to start believing in a market turn.

As stocks searched for direction yesterday, and ultimately closed with a slight loss, I called up Randy Watts, chief investment strategist and portfolio manager at LA-based investment advisor William O’Neil + Co., to sound out his views on where things stand nearly two months into a tariff-related market slump.

I’ve spoken with Watts often over the years, and like how he combines thoughts about market fundamentals (like earnings) with technical elements chart-watchers consult for clues on price moves.

Here are some highlights from our interview, edited for concision and clarity.

Sherwood News: How big a deal are the tariffs, and how do you see them impacting the market?

Randy Watts: If you talk to company managements about the supply chain, the constant changing of the tariffs and the rules is paralyzing American business and making it impossible to allocate capital. So even if we don’t have a recession, we are still slowing the economy because people are unable to make capital spending decisions.

Sherwood: I just wrote something about how some of the Mag 7 earnings estimates are really rolling over. Meta, Apple, Amazon — these stocks that have been so instrumental to the rally over the last few years — how important is that for the broader market?

Watts: First of all, I think earnings estimates are still too high for the year and need to come down. I don’t think the market can have a long-term sustainable rally without technology at least participating.

Sherwood: What’s your big-picture view at the moment? Where do you think the market stands?

Watts: Technically, the market does not look healthy right now.

We are waiting for a follow-through day, which is a day where the market goes up 1.7% or more on higher volume than the day before, but that’s after it has held its previous low for four days. So that big up day [April 9, when the S&P 500 jumped 9.5%] didn’t qualify as a follow-through day because the market hadn’t held the low for four days.

If you go back and look at the tech bubble and the great financial crisis, there were a bunch of days like that, where the market was up a ridiculous amount and then you made a lower low.

Having that extreme day where you’re up 10%, that’s actually not a true sign of market health. That’s a sign of volatility and instability.

Sherwood: What would be something that would give you more confidence that the market might have found its footing?

Watts: One of the things that gets us bullish and bearish is the number of technical setups in the market. Oftentimes we’re looking for a saucer or a cup-and-handle pattern. And right now you do not have a lot of stocks that look great technically. So, we’re still very cautious and telling clients to be cautious.

Sherwood: It sounds like you’re not at all convinced the bottom is in.

Watts: We are not convinced the bottom is in for a sure thing. We think earnings estimates are still too high and we’re not seeing the broad technical setups on individual stocks that we normally like to see at the start of a new bull market. So we’re continuing to tell clients to be cautious.

Sherwood: My experience covering the markets has been pretty Fed-centric since 2009, when I started. Do you think the Fed will come into play this year?

Watts: I believe the Fed will be forced to cut later in the year, and I think we’ll get two to five cuts. I think that’s coming. I also think the market, later in the year, can do better on Fed easing.

There are only two investment rules I believe: one is stop loss, and the other is “don’t fight the Fed.”

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.